Molecular profiling comparison of breast cancer subtypes in young women and older women
Antoinette R. Tan, Rebecca Feldman, James T. Symanowski, Qing Zhang, Julie G. Fisher, Lejla Hadzikadic-Gusic, Richard L. White Jr., Edward S. Kim
Young women with breast cancer (YWBC; ≤40 years) have a more aggressive clinical course and younger age of diagnosis is associated with a poorer prognosis.
The genomic landscape of YWBC remains largely unknown with the exception of predisposing germline mutations in BRCA1/2 (11-23% of YWBC).
We assessed molecular profiling data to explore patterns of biomarkers that may provide insight into the aggressive biology observed in younger patients.
We explored molecular features in tumor subtypes of YWBC and older women with breast cancer (OWBC; ≥65 years).
Somatic genomic profiles of 1879 breast tumors collected from 2013-2017 were assessed retrospectively and included in a de-identified data analysis if ER, PR and HER2 (immunohistochemistry [IHC] and/or in situ hybridization [ISH]) were available.
Testing included IHC, ISH and massively parallel sequencing assays (next generation sequencing [NGS]) at a CLIA-certified laboratory (Caris Life Sciences, Phoenix, AZ).
Pearson’s chi-square and regression analysis were utilized for comparisons and significance defined as p < 0.05.
There are distinct differences in the biology between young and older women with breast cancer.
These molecular changes may contribute to increased understanding of breast cancer tumor biology and refinement of treatment strategies in younger and older women with breast cancer.